Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Circulation. Population health and outcomes·2026
Same author

Identifying Contextual Barriers and Potential Solutions to Improving Hypertension Management in Rural Communities in the United States: Qualitative Study From 2 North Carolina Counties.

Journal of the American Heart Association·2026
Same author

Predicted versus observed outcomes in the ALT-FLOW early feasibility study.

ESC heart failure·2026
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.

Diabetes, obesity & metabolism·2026
Same journal

ERC consolidator grant: topology for understanding cardiac arrhythmia.

European heart journal·2026
Same journal

ALIGN-FMD Leducq funded network: Demystifying Fibromuscular Dysplasia.

European heart journal·2026
Same journal

Assessing the need for cardioverter defibrillator implantation in hypertrophic cardiomyopathy: patient association's perspectives.

European heart journal·2026
Same journal

Cardiovascular Grand Challenge: a new funding initiative by the British Heart Foundation.

European heart journal·2026
Same journal

The ESC President's Award 2025: Béla Merkely.

European heart journal·2026
Same journal

Underrepresentation of African patients in cardiology guidelines.

European heart journal·2026
See all related articles
  1. Home
  3. Albuminuria And Heart Failure.
  1. Home
  3. Albuminuria And Heart Failure.

Related Experiment Video

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Albuminuria and heart failure.

Javed Butler1,2, Adeena Jamil3, David Z I Cherney4

  • 1Baylor Scott and White Research Institute, 3434 Live Oak St Ste 501, Dallas, TX 75204, USA.

European Heart Journal
|June 12, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Albuminuria (urinary albumin-to-creatinine ratio) is a key risk marker for heart failure. Reducing albuminuria with therapies may improve cardiovascular and kidney outcomes, highlighting its potential as a modifiable factor.

Keywords:
AlbuminuriaChronic kidney diseaseHeart failureUrine albumin-to-creatinine ratio

More Related Videos

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

Related Experiment Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

Area of Science:

  • Cardiology
  • Nephrology
  • Clinical Medicine

Background:

  • Albuminuria is prevalent in heart failure patients and independently predicts adverse outcomes.
  • Current heart failure guidelines do not universally recommend albuminuria screening, unlike other conditions.
  • This lack of screening may hinder early detection and intervention.

Purpose of the Study:

  • To review the role of albuminuria in heart failure development and progression.
  • To explore albuminuria as a modifiable risk factor for cardiovascular and kidney outcomes.
  • To discuss measurement, guidelines, and the impact of therapies on albuminuria.

Main Methods:

  • Literature review of studies on albuminuria in heart failure.
  • Analysis of clinical trial data linking albuminuria reduction to improved outcomes.
  • Evaluation of current guideline recommendations and measurement techniques.

    • Main Results:

    • Albuminuria is a significant risk marker for incident and pre-existing heart failure.
    • Reductions in albuminuria correlate with reduced cardiovascular, heart failure, and kidney disease risks.
    • Emerging therapies show potential for modifying albuminuria and improving outcomes.

    Conclusions:

    • Albuminuria plays a crucial role in heart failure risk stratification and prognosis.
    • Screening for albuminuria in heart failure patients could enable earlier interventions.
    • Albuminuria may be a modifiable target for improving heart failure and related outcomes.